| [1] |
de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: Proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4( 5): 399- 411. DOI: 10.1016/S2468-1253(19)30047-0. |
| [2] |
de GOTTARDI A, SEMPOUX C, BERZIGOTTI A. Porto-sinusoidal vascular disorder[J]. J Hepatol, 2022, 77( 4): 1124- 1135. DOI: 10.1016/j.jhep.2022.05.033. |
| [3] |
RATTAN P, NGUYEN K, PENRICE DD, et al. Underrecognized association of Porto-sinusoidal vascular disorder and telomere biology disorders[J]. J Hepatol, 2025, 82( 4): e199- e200. DOI: 10.1016/j.jhep.2024.10.029. |
| [4] |
JAFARI P, EVARISTO G, DU XA, et al. Portosinusoidal vascular disorder: A heretofore unrecognized manifestation of sickle cell disease?[J]. Mod Pathol, 2024, 37( 1): 100351. DOI: 10.1016/j.modpat.2023.100351. |
| [5] |
MAGAZ M, GIUDICELLI-LETT H, ABRALDES JG, et al. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome[J]. J Hepatol, 2025, 82( 1): 72- 83. DOI: 10.1016/j.jhep.2024.07.035. |
| [6] |
OLIVAS P, PEREZ-CAMPUZANO V, ORTS L, et al. Porto-sinusoidal vascular disorder in chronic HBV: A significant coexistence not to be overlooked[J]. JHEP Rep, 2024, 6( 3): 100996. DOI: 10.1016/j.jhepr.2023.100996. |
| [7] |
HE YL, LIU H, LIU YN, et al. Clinical characteristics and outcomes of portal vein thrombosis in patients with porto-sinusoidal vascular disease: A cohort study[J]. J Clin Transl Hepatol, 2025, 13( 10): 825- 834. DOI: 10.14218/JCTH.2025.00093. |
| [8] |
MIRONOVA M, GOPALAKRISHNA H, KOH C, et al. Portal sinusoidal vascular diseases: Assessment and therapy[J]. Hepatology, 2025. DOI: 10.1097/HEP.0000000000001344.[ Epub ahead of print] |
| [9] |
Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome(2017, Nanjing)[J]. J Clin Hepatol, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003. |
| [10] |
KUMAR S, DELEVE LD, KAMATH PS, et al. Hepatic veno-occlusive disease(sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation[J]. Mayo Clin Proc, 2003, 78( 5): 589- 598. DOI: 10.4065/78.5.589. |
| [11] |
LIANG SK, YIN XC, ZHANG F, et al. Hepatic sinusoidal obstruction syndrome induced by Gynura segetum with portal vein thrombosis: A case report and literature review[J]. J Pract Hepatol, 2025, 28( 6): 954- 956. DOI: 10.3969/j.issn.1672-5069.2025.06.039. |
| [12] |
ZHOU AR, DA BL, LU WT, et al. Serum ascites albumin gradient in predicting the severity of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids[J]. Clin Exp Hepatol, 2025, 11( 2): 152- 159. DOI: 10.5114/ceh.2025.151628. |
| [13] |
CHENG Y, GU LH, YIN XC, et al. Agreement between wedged hepatic venous pressure and portal pressure in hepatic sinusoidal obstruction syndrome[J]. J Pers Med, 2022, 13( 1): 4. DOI: 10.3390/jpm13010004. |
| [14] |
Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenter, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176. |
| [15] |
RUBBIA-BRANDT L, LAUWERS GY, WANG HM, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis[J]. Histopathology, 2010, 56( 4): 430- 439. DOI: 10.1111/j.1365-2559.2010.03511.x. |
| [16] |
YU ZQ, LI W, TIAN C, et al. Drug-induced hepatic sinusoidal obstruction syndrome: Current advances and future perspectives[J]. Arch Toxicol, 2025, 99( 3): 835- 850. DOI: 10.1007/s00204-024-03950-9. |
| [17] |
ZHU C, REN XH, LIU D, et al. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome[J]. Toxicology, 2021, 460: 152882. DOI: 10.1016/j.tox.2021.152882. |
| [18] |
DAJTI E, SERENARI M, MALVI D, et al. Porto-sinusoidal vascular disorder in surgical candidates for liver metastases: Prevalence, noninvasive diagnosis, and burden on surgical outcomes[J]. Liver Transplant, 2025, 31( 1): 58- 69. DOI: 10.1097/lvt.0000000000000489. |
| [19] |
PUENTE A, FORTEA JI, DEL POZO C, et al. Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure[J]. Dig Liver Dis, 2024, 56( 10): 1721- 1729. DOI: 10.1016/j.dld.2024.04.010. |
| [20] |
CHEN XM, MA J, HE YS, et al. Characterization of liver injury induced by a pyrrolizidine alkaloid in rats[J]. Phytomedicine, 2021, 89: 153595. DOI: 10.1016/j.phymed.2021.153595. |
| [21] |
CAMPRECIÓS G, VILASECA M, TRIPATHI DM, et al. Interspecies transcriptomic comparison identifies a potentialporto-sinusoidalvascular disorder rat model suitable for in vivo drug testing[J]. Liver Int, 2024, 44( 1): 180- 190. DOI: 10.1111/liv.15765. |
| [22] |
MA J, ZHANG W, HE YS, et al. Clinical application of pyrrole-hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans[J]. Arch Toxicol, 2021, 95( 2): 759- 765. DOI: 10.1007/s00204-020-02947-4. |
| [23] |
ZHAO S, ZHANG H, ZHU HL, et al. Gut microbiota promotes macrophage M1 polarization in hepatic sinusoidal obstruction syndrome via regulating intestinal barrier function mediated by butyrate[J]. Gut Microbes, 2024, 16( 1): 2377567. DOI: 10.1080/19490976.2024.2377567. |
| [24] |
GIOIA S, CARNEVALE R, TAVANO D, et al. Association between gut-derived endotoxins and Porto-sinusoidal vascular disorder with portal hypertension[J]. Aliment Pharmacol Ther, 2023, 58( 11-12): 1205- 1216. DOI: 10.1111/apt.17727. |
| [25] |
PUGLIESE N, GIULI L, MASTROROCCO E, et al. Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease-A comprehensive narrative review[J]. Dig Liver Dis, 2024, 56( 6): 964- 970. DOI: 10.1016/j.dld.2023.11.021. |
DownLoad: